Francis X. McCormack, M.D., Yoshikazu Inoue, M.D., Ph.D., Joel Moss, M.D., Ph.D., Lianne G. Singer, M.D., Charlie Unusual, M.D., Koh Nakata, M.D., Ph.D., Alan F. Barker, M.D., Jeffrey T. Chapman, M.D., Mark L. Brantly, M.D., James M. Shares, M.D., Kevin K. Brown, M.D., Joseph P. Lynch, III, M.D., Hilary J. Goldberg, M.D., Lisa R. Adolescent, M.D., Brent W. Kinder, M.D., Gregory P. Downey, M.D., Eugene J. Sullivan, M.D., Thomas V. Colby, M.D., Roy T. McKay, Ph.D., Marsha M. Cohen, M.D., Leslie Korbee, B.S., Angelo M. Taveira-DaSilva, M.D., Ph.D., Hye-Seung Lee, Ph.D., Jeffrey P. Krischer, Ph.D., and Bruce C. Trapnell, M.D. For the National Institutes of Health Rare Lung Diseases Consortium and the MILES Trial Group: Efficacy and Protection of Sirolimus in Lymphangioleiomyomatosis..The proportion of sufferers with residual mitral regurgitation of at least moderate severity was significantly lower by adding mitral-valve repair; nevertheless, patients undergoing repair had more neurologic events than sufferers undergoing CABG only. At 1 year, this trial did not show a meaningful benefit of adding mitral-valve repair to CABG clinically. Longer-term follow-up may determine if the observed difference in the prevalence of moderate or serious mitral regurgitation at 12 months will translate into a net clinical benefit for patients undergoing repair.
ACT’s TEMPASURE cardiac ablation catheter receives CE Mark Advanced Cardiac Therapeutics, Inc.